Jacqueline P W Chung1, Alice K W Yiu2, Tony K H Chung2, Symphorosa S C Chan2. 1. Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Prince of Wales Hospital, New Territories, Hong Kong. Electronic address: jacquelinechung@cuhk.edu.hk. 2. Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Prince of Wales Hospital, New Territories, Hong Kong.
Abstract
OBJECTIVE: To investigate the effects of 4-month treatment of medroxyprogesterone acetate (MPA) and Diane-35 on the clinical and biochemical features of hyperandrogenism and quality of life of adolescent girls with polycystic ovarian syndrome (PCOS). DESIGN: A prospective, randomized, cross-over study. SETTING:An accredited pediatric and adolescent gynecology clinic of a university-affiliated tertiary hospital. PARTICIPANTS: 76 adolescents girls aged 14 to 19 years old with PCOS were recruited from July 2007 to July 2010. INTERVENTIONS: Girls were randomized into 2 groups. Group 1 received oral MPA for 4 months, followed by a washout period of 4 months, and then Diane-35 for another 4 months. Group 2 received the same combination but in the reverse order. MAIN OUTCOME MEASURES: Clinical and biochemical features of hyperandrogenism and quality of life were assessed. RESULTS: There was no significant difference between the 2 groups at baseline. No significant difference was found in the clinical and biochemical parameters of hyperandrogenism before and after treatment with MPA. Significant reduction of the acne score, LH/FSH ratio, and testosterone level was seen after taking Diane-35. Hirsutism was also improved but it did not reach statistical significant. When comparing post-MPA and post-Diane-35, the post-Diane-35 group had significantly improved acne score and LH/FSH ratio. No significant difference was found on quality of life between both groups after treatment. CONCLUSION: Diane-35 may be a more suitable treatment option in adolescent girls diagnosed with PCOS when compared to MPA.
RCT Entities:
OBJECTIVE: To investigate the effects of 4-month treatment of medroxyprogesterone acetate (MPA) and Diane-35 on the clinical and biochemical features of hyperandrogenism and quality of life of adolescent girls with polycystic ovarian syndrome (PCOS). DESIGN: A prospective, randomized, cross-over study. SETTING: An accredited pediatric and adolescent gynecology clinic of a university-affiliated tertiary hospital. PARTICIPANTS: 76 adolescents girls aged 14 to 19 years old with PCOS were recruited from July 2007 to July 2010. INTERVENTIONS:Girls were randomized into 2 groups. Group 1 received oral MPA for 4 months, followed by a washout period of 4 months, and then Diane-35 for another 4 months. Group 2 received the same combination but in the reverse order. MAIN OUTCOME MEASURES: Clinical and biochemical features of hyperandrogenism and quality of life were assessed. RESULTS: There was no significant difference between the 2 groups at baseline. No significant difference was found in the clinical and biochemical parameters of hyperandrogenism before and after treatment with MPA. Significant reduction of the acne score, LH/FSH ratio, and testosterone level was seen after taking Diane-35. Hirsutism was also improved but it did not reach statistical significant. When comparing post-MPA and post-Diane-35, the post-Diane-35 group had significantly improved acne score and LH/FSH ratio. No significant difference was found on quality of life between both groups after treatment. CONCLUSION:Diane-35 may be a more suitable treatment option in adolescent girls diagnosed with PCOS when compared to MPA.